Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Fenfluramine Hydrochloride

If you want to know more about the Fenfluramine Hydrochloride, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Fenfluramine Hydrochloride industry. More news about Fenfluramine Hydrochloride, are being released. Follow us / contact us for more Fenfluramine Hydrochloride information!
  • Drug Patent & Exclusivity Expiration Report - Week of Sep 22 2025

    Drug Patent & Exclusivity Expiration Report - Week of Sep 22 2025

    2025-09-22

    This week, there are 9 drugs in the patent and exclusivity list. They are: - AFT PHARMACEUTICALS US INC's COMBOGESIC, containing active ingredient ACETAMINOPHEN; IBUPROFEN - ACADIA PHARMACEUTICALS INC's NUPLAZID, containing active ingredient PIMAVANSERIN TARTRATE - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - SECURA BIO INC's COPIKTRA, containing active ingredient DUVELISIB - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - PFIZER INC's VIZIMPRO, containing active ingredient DACOMITINIB - HARROW EYE LLC's IHEEZO, containing active ingredient CHLOROPROCAINE HYDROCHLORIDE - JAZZ PHARMACEUTICALS RESEARCH UK LTD's EPIDIOLEX, containing active ingredient CANNABIDIOL - INSMED INC's ARIKAYCE KIT, containing active ingredient AMIKACIN SULFATE Read More